Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 14/20 | 0.57 |
| ▸ | NPFFR2 | Q9Y5X5 | 14/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502727 | 0.89 | NPFFR1 (0.56) | NPFFR1NPFFR2OPRK1SIGMAR1ALDH1A1 | |
| SCHEMBL6635524 | 0.87 | NPFFR1 (0.62) | NPFFR1NPFFR2OPRK1SIGMAR1IDO1 | |
| SCHEMBL16926455 | 0.85 | NPFFR1 (0.60) | NPFFR1NPFFR2OPRK1SIGMAR1ALDH1A1 | |
| SCHEMBL23268368 | 0.84 | NPFFR1 (0.59) | NPFFR1NPFFR2SIGMAR1ALDH1A1IDO1 | |
| SCHEMBL4511211 | 0.84 | NPFFR1 (0.59) | NPFFR1NPFFR2SIGMAR1ALDH1A1IDO1 | |
| SCHEMBL2281940 | 0.84 | NPFFR1 (0.59) | NPFFR1NPFFR2SIGMAR1ALDH1A1IDO1 | |
| SCHEMBL19705065 | 0.83 | NPFFR1 (0.49) | NPFFR1NPFFR2SIGMAR1ALDH1A1 | |
| SCHEMBL4517495 | 0.83 | NPFFR1 (0.57) | NPFFR1NPFFR2SIGMAR1IDO1 | |
| SCHEMBL9181182 | 0.83 | NPFFR1 (0.57) | NPFFR1NPFFR2SIGMAR1ALDH1A1IDO1 | |
| SCHEMBL2348786 | 0.82 | NPFFR1 (0.64) | NPFFR1NPFFR2SIGMAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582627-B2 | 3-Amino-7-[3-(1-aminoethyl)-4-fluoropyrrolidin-1-yl]-1-cyclopropyl-8-methyl-1H-pyrido[4,3-d]pyrimidine-2,4-dione; quinolone antibiotics; bactericides; for antibiotic- resistant bacterial infections, ciprofloxacin- resistant ones; inhibiting wild-type and quinolone- resistant mutants of DNA gryase | WARNER-LAMBERT COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1255739-B1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20060287308-A1 | 3-Aminoquinazolin-2,4-dione antibacterial agents | ZOETIS WLC LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094780-B1 | 3-aminoquinazolin-2,4-dione antibacterial agents | WARNER LAMBERT COMPANY LLC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ZOETIS WLC LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1255739-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001053273-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ABL1, NQO2, CBR3 | NPFFR1 781/4885NPFFR2 828/4885OPRK1 218/4885 |
| US-20060287308-A1 | 3-Aminoquinazolin-2,4-dione antibacterial agents | ABL1, NQO2, AAAS | NPFFR1 785/4885NPFFR2 873/4885OPRK1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.